| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae10212794160b34478f0d05b6ab6fd7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-14 |
| filingDate |
2020-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_523d5771d3b68963832fe1c69064f752
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc89b72593fd856cc81c1f1e077be17a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9e3042849052fc2c35954d54b17e48e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7058e7002ee47f7e0c664eca419beb21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7b4d147b4ae285ebc20416baba7e609
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2314800d2102555863cd5bd35929bac4 |
| publicationDate |
2022-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2020372333-A1 |
| titleOfInvention |
Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| abstract |
A method of identifying a subject having a hematological cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the hematological cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3. |
| priorityDate |
2019-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |